Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06481826

Glofitamab in Chinese Patients With R/R DLBCL

Sponsor: Peking Union Medical College Hospital

View on ClinicalTrials.gov

Summary

This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.

Official title: A Study to Evaluate Glofitamab as Single Agent in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

OBSERVATIONAL

Enrollment

20

Start Date

2024-01-01

Completion Date

2028-12-31

Last Updated

2026-03-27

Healthy Volunteers

No

Interventions

DRUG

Glofitamab

Glofitamab given in standard dosage

Locations (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China